199522-66-2

Usage

Uses

Used in Pharmaceutical Research:
N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine is utilized as a key intermediate in the synthesis of biologically active compounds, particularly for the development of antiviral and anticancer agents. Its unique structure allows for the design of novel therapeutic drugs that target specific biological pathways, offering potential in the treatment of various diseases.
Used in Organic Synthesis:
In the field of organic synthesis, N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine is employed as a versatile building block. Its reactivity and functional groups enable the formation of a wide range of chemical products, contributing to the advancement of chemical research and the discovery of new materials.
Used in Medicinal Chemistry:
N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine holds significant value in medicinal chemistry, where it is used to explore and develop new drug candidates. Its structural features facilitate the creation of compounds with potential therapeutic applications, making it an essential component in drug discovery processes.

InChI:InChI=1/C7H10BrN3/c8-6-1-2-7(11-5-6)10-4-3-9/h1-2,5H,3-4,9H2,(H,10,11)

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 107-15-3 ethylenediamine 

Downstream Products

• 207276-79-7 N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)ethane-1,2-diamine 
• 866930-72-5 tert-butyl {2-[(5-bromopyridin-2-yl)amino]ethyl}carbamate 
• 1401342-14-0 C₂₂H₂₅FN₆O₃ 
• 1401342-13-9 C₂₃H₂₃FN₆O₃ 
• 1401342-12-8 C₂₂H₂₃FN₆O₅ 
• 1401342-11-7 C₂₀H₂₁FN₆O₃*ClH 
• 1401342-10-6 C₂₁H₂₁FN₆O₄ 

Relevant academic research and scientific papers

BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS

The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt therof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME

Disclosed is a novel oxazolidinone derivative represented by Formula 1 above, in particular, a novel oxazolidinone compound having a cyclic amidoxime or cyclic amidrazone group. In Formula 1, R and Q are the same as defined in the detailed description. In addition, disclosed is a pharmaceutical composition for an antibiotic which includes the novel oxazolidinone derivative of Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The novel oxazolidinone derivative, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically acceptable salt thereof have broad antibacterial spectrum against resistant bacteria, low toxicity and strong antibacterial effects against Gram-positive and Gram-negative bacteria and thus may be effectively used as antibiotics.

NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME

Disclosed is a novel oxazolidinone derivative represented by Formula 1 above, in particular, a novel oxazolidinone compound having a cyclic amidoxime or cyclic amidrazone group. In Formula 1, R and Q are the same as defined in the detailed description. In addition, disclosed is a pharmaceutical composition for an antibiotic which includes the novel oxazolidinone derivative of Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The novel oxazolidinone derivative, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically acceptable salt thereof have broad antibacterial spectrum against resistant bacteria, low toxicity and strong antibacterial effects against Gram-positive and Gram-negative bacteria and thus may be effectively used as antibiotics.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Nonpeptide somatostatin agonists with sst4 selectivity: Synthesis and structure-activity relationships of thioureas

Utilizing NNC 26-9100 (11) as a structural lead, a variety of nonpeptide derivatives of somatostatin were synthesized and evaluated for sst2 and sst4 receptor binding affinity. A novel thiourea scaffold was utilized to attach (1) a h